INM

InMed Pharmaceuticals Inc. is a pharmaceutical company developing novel therapies through the research and development of cannabinoid-based medications. The company focuses on diseases with high unmet medical needs, including epidermolysis bullosa, a rare genetic skin disorder, and glaucoma. InMed has developed proprietary biosynthesis technology to manufacture pharmaceutical-grade cannabinoids at commercial scale, reducing reliance on traditional plant-based extraction. The company's pipeline includes both topical and ocular drug candidates targeting specific medical conditions where cannabinoids may provide therapeutic benefits.